Mesoblast is using its proprietary mesenchymal lineage cell technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex inflammatory diseases resistant to conventional standard of care.
The Company’s portfolio of Phase 3 product candidates are:
- Remestemcel-L for steroid-refractory acute graft versus host disease (acute GVHD) in children
- Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection
- REVASCOR® for advanced chronic heart failure
- MPC-06-ID for chronic low back pain due to degenerative disc disease
The Company also has a promising emerging pipeline and next generation technologies.
Innovative technology platform
Mesoblast’s novel allogeneic product candidates are based on rare (approximately 1:100,000 in bone marrow) mesenchymal lineage cells that respond to tissue damage, secreting mediators that promote tissue repair and modulate immune responses.
Mesenchymal lineage cells are collected from the bone marrow of healthy adult donors and proprietary processes are utilized to expand them to a uniform, well characterized, and highly reproducible cell population. This enables manufacturing at industrial scale for commercial purposes. Another key feature of Mesoblast’s cells is they can be administered to patients without the need for donor–recipient matching or recipient immune suppression.
Events
February 11, 2021
Mesoblast Phase 3 Chronic Low Back Pain Results
January 11, 2021
Presentation at H.C. Wainwright BioConnect 2021 Conference
December 18, 2020
Mesoblast Update on COVID-19 ARDS Trial
December 15, 2020
Mesoblast Phase 3 Chronic Heart Failure Results
Latest News
26 February 2021
Half Year Report and Accounts (including Appendix 4D) >
26 February 2021
Trading Halt >
17 February 2021
Remestemcel-L for COVID-19 MIS-C published in Pediatrics >
11 February 2021
Mesoblast Phase 3 Chronic Low Back Pain Results >
11 February 2021
Mesoblast Corporate Update Webcast >